FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development

The FDA has finalized its guidance for industry on clinical investigations of psychedelic drugs, providing sponsors with general considerations for developing compounds such as psilocybin, LSD, and MDMA as treatments for psychiatric disorders and substance use disorders. The document finalizes a draft issued in June 2023.¹

Drug development programs for psychedelic drugs are subject to the same regulations and evidentiary standards for approval as other drug development programs, but designing clinical studies to evaluate their safety and effectiveness presents a number of unique challenges.²

Psychedelic drugs can cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days. Some development programs incorporate a psychological or behavioral intervention alongside drug administration. Investigators hypothesize that psychedelic drugs have both rapid-onset and long-term benefits after only one or a few doses.

"These and other unusual characteristics should be considered when designing clinical studies so that the results of those studies can provide reliable data on efficacy and safety," the guidance states.

Rather than providing specific study design recommendations, the guidance presents foundational constructs for all sponsors studying the therapeutic potential of psychedelic drugs to consider, including academic researchers without commercial drug development as a primary interest. Sponsors are encouraged to request meetings with the FDA for advice on specific development programs.

Functional unblinding and trial design

Designing an adequate and well-controlled clinical investigation of psychedelic drugs is challenging given the often intense perceptual changes the drugs induce. This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters—which can lead to expectation bias in those who experience perceptual disturbances, or in those who observe them.

Given these concerns, the use of a traditional placebo as a control can be problematic for assessing efficacy. The guidance encourages consideration of alternatives, such as lower doses of a psychedelic or other psychoactive drugs that mimic some aspects of the subjective experience. The agency also recommends the use of central raters blinded to treatment allocation, blinding questionnaires for both subjects and investigators, and expectancy evaluation questionnaires administered before randomization and at the end of treatment.

"Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding," the guidance states.

Durability, repeat dosing, and psychotherapy

Although investigators hypothesize that one or a few doses of a psychedelic drug will produce lasting therapeutic benefit, many of the conditions these drugs are purported to treat typically persist for months or years.

For products intended to treat chronic conditions such as PTSD or major depressive disorder, the FDA recommends evaluating treatment effect at 12 weeks using a double-blind design, followed by continued follow-up to monitor for symptom recurrence and potential need for repeat dosing.

The most informative design would incorporate blinded long-term follow-up of typically 12 months with prespecified criteria for retreatment.

Many programs pair drug administration with psychological support or psychotherapy. The guidance notes that as of its publication date, the contribution of the psychotherapy component to any observed efficacy has not been characterized, and recommends that sponsors consider factorial designs to distinguish the drug's contribution from that of the therapy.

Safety monitoring

Because subjects receiving psychedelic drugs may remain in a vulnerable state for several hours or longer, the guidance specifies that safety monitoring during treatment sessions should include observation by two monitors: a lead monitor with graduate-level professional training and independent licensure in psychotherapy, and an assistant monitor with at least one year of clinical experience in a licensed mental health setting. If the lead monitor is not a physician, a licensed on-call physician must be able to reach the clinical site within 15 minutes in the event of a medical emergency.

Abuse potential

Because many psychedelic drugs are Schedule I controlled substances under the Controlled Substances Act, abuse potential assessment and a proposal for drug scheduling are required components of a new drug application.

The guidance notes that self-administration and conditioned place preference studies are not usually required for psychedelic drugs, as they typically do not produce positive signals in those studies.

A human abuse potential study may not be scientifically necessary when subjective effects predictive of abuse are already well-characterized from extensive clinical studies and robust epidemiological data. Sponsors are encouraged to discuss their abuse potential assessment plans with the FDA early in the IND stage.

References

1. Psychedelic Drugs: Considerations for Clinical Investigations. FDA. July 2026. Accessed July 15, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

2. Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry. HHS. FDA. CDER. July 2026. Accessed July 15, 2026. https://www.fda.gov/media/169694/download